Published in Women's Health Weekly, July 10th, 2008
"Women continuing therapy were reassessed at 4 and 6 months and 1 year with a review of all treatments after 1 year. At each visit, they were asked about persistence with duloxetine, reasons for discontinuation and any alternative treatments. Seventy-one (31%) women continued beyond 4 weeks of treatment, and twenty-six (12%)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.